Back

Clinical utility of the FIB-4 index for predicting cardiovascular outcomes in patients with metabolic dysfunction-associated steatotic liver disease: a 10-year retrospective cohort study

30 August 2025 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Autoimmunity in focus Autoimmune/Chronic Inflammatory Disorders and Heart Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Padoemwut Teerawongsakul

Faculty of Medicine Vajira Hospital, Bangkok (Thailand)

4 More presentations in this session

Presentation thumbnail
Assessment of the accuracy of the HeartInsight system in predicting worsening heart failure in Japanese patients: A comparison between females and males
Doctor Y. Takanashi (Chiba, JP)
Abstract Slides Video
Presentation thumbnail
The risk of incident atrial fibrillation in patients with inflammatory arthritis: a hierarchical clustering approach from the Hong Kong Hospital Authority Data Collaboration Laboratory (HADCL)
Doctor S. Lam (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Prevalence and prognostic utility of cirrhotic cardiomyopathy among patients with liver cirrhosis
Doctor I. Dimitroglou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The effect of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx integrity and vascular function in patients with psoriasis
Doctor D. Vlachomitros (Marousi, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Autoimmunity in focus

The Event

Event poster

ESC Congress 2025

30 August 2025 08:15 CET
You may be interested in
thumbnail
Congress Presentation
The product of bilirubin and trigliseride is the most significant predictor of severe FIB-4 index of liver disease in cardiac patients
thumbnail
Congress Presentation
An Elevated FIB-4 Score is associated with the severity of heart failure
thumbnail
Congress Presentation
Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources